|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hidalgo M, Cascinu S, Kleeff J, Labianca
R, Löhr JM, Neoptolemos J, Real FX, Van Laethem JL and Heinemann V:
Addressing the challenges of pancreatic cancer: Future directions
for improving outcomes. Pancreatology. 15:8–18. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Maitra A and Hruban RH: Pancreatic cancer.
Ann Rev Pathol. 3:157–188. 2008. View Article : Google Scholar
|
|
4
|
Javadi S, Karbasian N, Bhosale P, de
Castro Faria S, Le O, Katz MH, Koay EJ and Tamm EP: Imaging
findings of recurrent pancreatic cancer following resection. Abdom
Radiol (NY). 43:489–496. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Suzuki A, Kusakai G, Kishimoto A, Lu J,
Ogura T, Lavin MF and Esumi H: Identification of a novel protein
kinase mediating Akt survival signaling to the ATM protein. J Biol
Chem. 278:48–53. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Warfel NA and Kraft AS: PIM kinase (and
Akt) biology and signaling in tumors. Pharmacol Ther. 151:41–49.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ekstrand AI, Jonsson M, Lindblom A, Borg A
and Nilbert M: Frequent alterations of the PI3K/AKT/mTOR pathways
in hereditary nonpolyposis colorectal cancer. Fam Cancer.
9:125–129. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li B, Tsao SW, Li YY, Wang X, Ling MT,
Wong YC, He QY and Cheung AL: Id-1 promotes tumorigenicity and
metastasis of human esophageal cancer cells through activation of
PI3K/AKT signaling pathway. Int J Cancer. 125:2576–2585. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ohta T, Isobe M, Takahashi T,
Saitoh-Sekiguchi M, Motoyama T and Kurachi H: The Akt and ERK
activation by platinum-based chemotherapy in ovarian cancer is
associated with favorable patient outcome. Anticancer Res.
29:4639–4647. 2009.PubMed/NCBI
|
|
10
|
Simon PO Jr, McDunn JE, Kashiwagi H, Chang
K, Goedegebuure PS, Hotchkiss RS and Hawkins WG: Targeting AKT with
the proapoptotic peptide, TAT-CTMP: A novel strategy for the
treatment of human pancreatic adenocarcinoma. Int J Cancer.
125:942–951. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Esumi H, Izuishi K, Kato K, Hashimoto K,
Kurashima Y, Kishimoto A, Ogura T and Ozawa T: Hypoxia and nitric
oxide treatment confer tolerance to glucose starvation in a
5′-AMP-activated protein kinase-dependent manner. J Biol Chem.
277:32791–3298. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Suzuki A, Kusakai G, Shimojo Y, Chen J,
Ogura T, Kobayashi M and Esumi H: Involvement of transforming
growth factor-beta 1 signaling in hypoxia-induced tolerance to
glucose starvation. J Biol Chem. 280:31557–31563. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Suzuki A, Lu J, Kusakai G, Kishimoto A,
Ogura T and Esumi H: ARK5 is a tumor invasion-associated factor
downstream of Akt signaling. Mol Cell Biol. 24:3526–3535. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Suzuki A, Ogura T and Esumi H: NDR2 acts
as the upstream kinase of ARK5 during insulin-like growth factor-1
signaling. J Biol Chem. 281:13915–21391. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kusakai G, Suzuki A, Ogura T, Kaminishi M
and Esumi H: Strong association of ARK5 with tumor invasion and
metastasis. J ExpClin Cancer Res. 23:263–268. 2004.
|
|
16
|
Cui J, Yu Y, Lu GF, Liu C, Liu X, Xu YX
and Zheng PY: Overexpression of ARK5 is associated with poor
prognosis in hepatocellular carcinoma. Tumour Biol. 34:1913–1918.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chang XZ, Yu J, Liu HY, Dong RH and Cao
XC: ARK5 is associated with the invasive and metastatic potential
of human breast cancer cells. J Cancer Res Clin Oncol. 138:247–254.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sun X, Gao L, Chien HY, Li WC and Zhao J:
The regulation and function of the NUAK family. J Mol Endocrinol.
51:R15–R22. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kusakai G, Suzuki A, Ogura T, Miyamoto S,
Ochiai A, Kaminishi M and Esumi H: ARK5 expression in colorectal
cancer and its implications for tumor progression. Am J Pathol.
164:987–995. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lu S, Niu N, Guo H, Tang J, Guo W, Liu Z,
Shi L, Sun T, Zhou F, Li H, et al: ARK5 promotes glioma cell
invasion, and its elevated expression is correlated with poor
clinical outcome. Eur J Cancer. 49:752–763. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen P, Li K, Liang Y, Li L and Zhu X:
High NUAK1 expression correlates with poor prognosis and involved
in NSCLC cells migration and invasion. Exp Lung Res. 39:9–17. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang X, Song Z, Chen F, Yang X, Wu B, Xie
S, Zheng X, Cai Y, Chen W and Zhong Z: AMPK-related kinase 5 (ARK5)
enhances gemcitabine resistance in pancreatic carcinoma by inducing
epithelial-mesenchymal transition. Am J Transl Res. 10:4095–4106.
2018.PubMed/NCBI
|
|
23
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Vivian J, Rao AA, Nothaft FA, Ketchum C,
Armstrong J, Novak A, Pfeil J, Narkizian J, Deran AD,
Musselman-Brown A, et al: Toil enables reproducible, open source,
big biomedical data analyses. Nat Biotechnol. 35:314–316. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
von Mering C, Jensen LJ, Snel B, Hooper
SD, Krupp M, Foglierini M, Jouffre N, Huynen MA and Bork P: STRING:
Known and predicted protein-protein associations, integrated and
transferred across organisms. Nucleic Acids Res. 33((Database
Issue)): D433–D437. 2005.PubMed/NCBI
|
|
26
|
Zhou Y, Zhou B, Pache L, Chang M,
Khodabakhshi AH, Tanaseichuk O, Benner C and Chanda SK: Metascape
provides a biologist-oriented resource for the analysis of
systems-level datasets. Nat Commun. 10:15232019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shannon P, Markiel A, Ozier O, Baliga NS,
Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A
software environment for integrated models of biomolecular
interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Remmele W and Stegner HE: Recommendation
for uniform definition of an immunoreactive score (IRS) for
immunohistochemical estrogen receptor detection (ER-ICA) in breast
cancer tissue. Pathologe. 8:138–140. 1987.(In German). PubMed/NCBI
|
|
29
|
McGuigan A, Kelly P, Turkington RC, Jones
C, Coleman HG and McCain RS: Pancreatic cancer: A review of
clinical diagnosis, epidemiology, treatment and outcomes. World J
Gastroenterol. 24:4846–4861. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu H, Ma Q, Xu Q, Lei J, Li X, Wang Z and
Wu E: Therapeutic potential of perineural invasion, hypoxia and
desmoplasia in pancreatic cancer. Curr Pharm Des. 18:2395–2403.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu L, Ulbrich J, Müller J, Wüstefeld T,
Aeberhard L, Kress TR, Muthalagu N, Rycak L, Rudalska R, Moll R, et
al: Deregulated MYC expression induces dependence upon AMPK-related
kinase 5. Nature. 483:608–612. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Rajamani D and Bhasin MK: Identification
of key regulators of pancreatic cancer progression through
multidimensional systems-level analysis. Genome Med. 8:382016.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Huang X, Lv W, Zhang JH and Lu DL: miR-96
functions as a tumor suppressor gene by targeting NUAK1 in
pancreatic cancer. Int J Mol Med. 34:1599–1605. 2014. View Article : Google Scholar : PubMed/NCBI
|
